Skip Navigation

Journal of Antimicrobial Chemotherapy 2005 56(Supplement 1):i39-i48; doi:10.1093/jac/dki223
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herbrecht, R.
Right arrow Articles by Letscher-Bru, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbrecht, R.
Right arrow Articles by Letscher-Bru, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Supplement

Management of systemic fungal infections: alternatives to itraconazole

R. Herbrecht1,*, Y. Nivoix2, C. Fohrer1, S. Natarajan-Amé1 and V. Letscher-Bru3

1 Department of Haematology and Oncology, Hôpital de Hautepierre, 67098 Strasbourg, France; 2 Department of Pharmacy, Hôpital de Hautepierre, 67098 Strasbourg, France; 3 Institut de Parasitologie et de Pathologie Tropicale, 3 rue Koeberlé, 67000 Strasbourg, France

* Corresponding author. Tel: +33-388-12-76-88; Fax: +33-388-12-76-81; E-mail: raoul.herbrecht{at}chru-strasbourg.fr

For many years, amphotericin B and flucytosine have been the only antifungal agents for invasive fungal infections. Amphotericin B was the standard of care for most of these infections. However, its use was often associated with low efficacy and poor tolerance. Fortunately, the antifungal armamentarium has increased during the past two decades with the addition of several new agents. In addition to itraconazole and fluconazole, lipid formulations of amphotericin B, voriconazole, caspofungin and micafungin have arrived on the market. Other agents are expected to be licensed shortly (anidulafungin, posaconazole). These various antifungal agents differ in their spectrum, pharmacokinetic profile, route of administration, efficacy in clinical trials, safety profile, drug–drug interactions and, importantly, their cost. There is no longer a unique standard agent for all or nearly all invasive fungal infections but a real choice among several agents. The characteristics of these new agents are reviewed to help clinicians in their decision to select an antifungal agent for their patients.

Keywords: antifungals , azoles , amphotericin B


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. Al-Badriyeh, D. Liew, K. Stewart, and D. C. M. Kong
Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia
J. Antimicrob. Chemother., June 1, 2009; 63(6): 1276 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. I. Morris
Posaconazole: A new oral antifungal agent with an expanded spectrum of activity
Am. J. Health Syst. Pharm., February 1, 2009; 66(3): 225 - 236.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.